LTBR and glioblastoma: LTβR agonistic antibodies (anti-LTβR) were also reported to induce MECA-79+ TA-HEV and to enhance lymphocyte infiltration in distinct mouse tumor models, and treatment with anti-LTβR enabled response to anti-VEGFR2 and anti-PD-L1 combination therapy in a recalcitrant glioblastoma model [287].